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DOI 10.1016/j.ccr.2011.04.008SUMMARYProstate cancer is characterized by its dependence on androgen receptor (AR) and frequent activation of
PI3K signaling. We find that AR transcriptional output is decreased in human and murine tumors with
PTEN deletion and that PI3K pathway inhibition activates AR signaling by relieving feedback inhibition of
HER kinases. Similarly, AR inhibition activates AKT signaling by reducing levels of the AKT phosphatase
PHLPP. Thus, these two oncogenic pathways cross-regulate each other by reciprocal feedback. Inhibition
of one activates the other, thereby maintaining tumor cell survival. However, combined pharmacologic inhi-
bition of PI3K and AR signaling caused near-complete prostate cancer regressions in aPten-deficient murine
prostate cancer model and in human prostate cancer xenografts, indicating that both pathways coordinately
support survival.INTRODUCTION
Prostate cancer is the most common malignancy diagnosed in
males and the second most common cause of male cancer
deaths (American Cancer Society, 2010). Despite advances
made in the early detection and treatment of localized prostate
cancer, the American Cancer Society estimates that 32,050
men will have died of metastatic disease in 2010. Androgen-
deprivation therapy remains the standard treatment ofmetastatic
prostate cancer; however, progression to castrate resistance
disease occurs in the majority of patients (Rini and Small, 2002;
Singh et al., 2010). Following the emergence of castrate-resistant
prostate cancer, docetaxel chemotherapy has been shown to beSignificance
The two most frequently activated signaling pathways in pros
Inhibitors of the PI3K pathway are in early clinical trials, and
However, these inhibitors rarely induce tumor regression in pre
each other by reciprocal negative feedback, such that inhibitio
and survive when either single pathway is inhibited pharmaco
with combined pathway inhibition in preclinical prostate tum
patients.therapeutically efficacious; however, the median increase in
survival was only 4 months (Petrylak et al., 2004). Thus, there is
a significant need for improvements in therapy for prostate
cancer.
The PI3K pathway plays a central role in tumorigenesis across
a variety of malignancies (Courtney et al., 2010; Liu et al., 2009).
Prostate cancers are associated with genetic alterations
involving the PI3K and androgen receptor (AR) pathways, both
of which mediate survival signals in prostate cancer. Roughly
40% of primary and 70% of metastatic prostate cancers have
genomic alterations in the PI3K-signaling pathway, mostly
through loss of PTEN (El Sheikh et al., 2008; Reid et al., 2010;
Taylor et al., 2010). Preclinical studies of mice with conditional,tate cancer are driven by androgen receptor (AR) and PI3K.
AR inhibitors confer clinical responses in most patients.
clinical models. Here, we show that these pathways regulate
n of one activates the other. Therefore, tumor cells can adapt
logically. Our demonstration of profound tumor regressions
or models provides rationale for combination therapy in
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Dual PI3K/AR Pathway Inhibition in Prostate Cancerprostate-specific Pten deletion and of cell lines with stable
silencing of Pten by RNA interference have established that
loss of PTEN promotes resistance to castration (Gao et al.,
2006; Jiao et al., 2007). However, this effect of PTEN loss is
not absolute because certain prostate cancer xenograft models
with PTEN loss (LNCaP, LAPC9) remain at least partially
sensitive to castration (Craft et al., 1999). Furthermore, the
high clinical response rate to castration therapy indicates that
at least some PTEN-deficient tumors retain some degree of
sensitivity.
The critical role of PTEN in regulating flux through the
PI3K-signaling pathway raises the possibility that PI3K pathway
inhibitors might be effective in PTEN-deficient prostate cancer.
Indeed, genetic loss of either mTOR or AKT1 is sufficient to
significantly reduce the initiation of prostate cancer in the condi-
tionalPtenmodel (Chen et al., 2006; Guertin et al., 2009; Nardella
et al., 2009). The mTORC1 inhibitor rapamycin has been shown
to revert early PIN lesions in youngmAKTmice; however, results
in Pten prostate conditional null mouse models have been
modest (Majumder et al., 2004; Zhang et al., 2009). Furthermore,
clinical trials of rapamycin analogs in castration-resistant pros-
tate cancer have failed to demonstrate clinical activity (George
et al., 2008, J. Clin. Oncol., abstract). One potential liability of
mTORC1 inhibition is disruption of a negative feedback loop,
resulting in hyperactivation of AKT and MAPK that can promote
cell survival independent of mTORC1, thereby limiting thera-
peutic efficacy (Carracedo et al., 2008; O’Reilly et al., 2006;
Sarbassov et al., 2005).
The availability of a number of PI3K pathway inhibitors in
clinical development targeting various critical components of
the pathway (PI3K, AKT, mTORC1/2) allows this issue to be
readdressed (Serra et al., 2008). The goal of our study was to
evaluate the therapeutic efficacy of PI3K pathway inhibition in
preclinical models of prostate cancer and to define themolecular
mechanism of PI3K and AR feedback regulation. Through this
work we propose combination therapy based on targeting
compensatory survival pathways associated with relief of feed-
back inhibition observed following PI3K or AR inhibition.
RESULTS
Inhibition of thePI3KPathwayCausesGrowthArrest but
Not Significant Tumor Regression in Pten-Negative
Prostate Cancers
We evaluated the therapeutic efficacy of PI3K pathway inhibition
in mice with established prostate cancers caused by either
conditional deletion of Pten (Ptenlox/lox PB-Cre, hereafter called
Ptenlox/lox) or transgenic expression of MYC (PB-MYC) using
BEZ235, a dual PI3K and mTORC1/2 inhibitor (Serra et al.,
2008). PB-MYC mice were chosen because MYC amplification
or overexpression is also commonly found in human tumors.
This model likely represents a subset of human prostate cancer
distinct from that driven by PTEN loss. PI3K/mTOR inhibition
was confirmed in the Ptenlox/lox mice using pAKT and pS6 and
in the PB-MYC mice using pS6 (Figure 1A; see Figure S1A
available online). Cell proliferation as measured by Ki67 staining
was significantly reduced in the Ptenlox/lox mice (proportion of
positive cells: 0.34 versus 0.15, for vehicle control and
BEZ235, respectively; p < 0.01), but not in PB-MYC mice576 Cancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc.(Figures 1B and 1C). However, there was minimal reduction in
prostate cancer tumor volume as measured by MRI (mean
volume reduction of 14.75%) and no obvious effect on tumor
histology (Figures 1B, 1D, and 1E). PB-MYC prostate cancers
showed no radiographic or histologic response (Figures 1B–
1E). In summary, BEZ235 has modest, primarily cytostatic,
activity in Ptenlox/lox mice, but no activity in PB-MYC mice,
consistent with earlier in vitro studies in breast cancer cell lines
(Brachmann et al., 2009).
Inhibition of the PI3K Pathway Activates the ARPathway
in PTEN-Negative Prostate Cancers
Given the critical role of AR in prostate cancer initiation and
progression, we hypothesized that sustained AR activity might
explain the persistent survival of Pten null prostate cells in
Ptenlox/lox mice treated with BEZ235. To our surprise, we found
that Ptenlox/lox mice had reduced AR protein levels compared
to their Pten wild-type littermates. Treatment of Ptenlox/lox mice
with BEZ235 partially rescued AR protein levels, indicating that
increased PI3K/mTOR activity likely explains the decrease in
AR levels (Figure 2A). Similar effects of PI3K/mTOR inhibition
(BEZ235) or mTORC1 (RAD001) inhibition on AR protein levels
were observed in the PTEN-deficient human prostate cancer
cell line LNCaP (Figure 2B). As expected from earlier studies
with rapamycin (Carracedo et al., 2008), p-ERK levels were
increased following treatment with either BEZ235 or RAD001
(Figure 2B). Thus, PI3K pathway inhibition in PTEN-deficient
prostate cancer resulted in the activation of two critical cell
survival pathways (AR and MAPK).
We next evaluated whether the increase in AR protein levels
seenwith PI3K pathway inhibition resulted in increased AR target
gene activity. Indeed, mRNA levels of three canonical AR target
genes, Pbsn, Nkx3.1, and Psca, were increased by short-term
treatment of Ptenlox/lox mice with BEZ235 (Figure 2C). Similarly,
the activity of an androgen-responsive reporter gene was
increased in LNCaP cells exposed to BEZ235 or RAD001,
consistent with other reports using rapamycin (Figure 2D) (Lin
et al., 2003; Wang et al., 2008). Increased androgen-responsive
reporter gene activity was also observed following treatment
with an allosteric, highly specific, inhibitor of AKT1 and AKT2,
providing further evidence that these pharmacologic effects
are due to PI3K pathway blockade (Figure 2D). Collectively,
the data from these PTEN-deficient murine and human models
indicate that PI3K pathway inhibitors can activate AR target
gene expression.
HER family receptor tyrosine kinases and the insulin-like
growth factor receptor (IGFR) are feedback inhibited by the
PI3K pathway and reactivated in breast tumor cell lines and
xenograft models exposed to AKT inhibitors (Chandarlapaty
et al., 2011). Consistent with these data, others have found
that inhibition of PI3K pathway in breast cancer cell lines results
in upregulation of HER3 (Yao et al., 2009). Therefore, we consid-
ered that similar effects may be seen in PTEN-deficient prostate
cancers. Indeed, the level of HER3 was increased in LNCaP cells
and in prostates of Ptenlox/lox mice after exposure to BEZ235
(Figure 2E). To address potential off-target effects associated
with pharmacologic inhibition of PI3K pathway kinases, we
targeted AKT1/2 using siRNA. AKT1/2 knockdown led to upre-
gulation of both HER3 and AR, as well as pERK similar to that
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Figure 1. Preclinical Trial of PI3K Pathway Inhibition in GEM Models of Prostate Cancer
(A) Target inhibition was confirmed with BEZ235 treatment (45 mg/kg/day) by analyzing the expression of pAkt and pS6 in the Ptenlox/lox mice (microscopy
at 4003).
(B) Histologic and immunohistochemical staining for ki67 in PB-MYC and Ptenlox/lox mice treated with vehicle control or BEZ235 (microscopy at 2003).
(C) Quantification of ki67 staining (mean of three HPF ±SD) for PB-MYC and Ptenlox/lox mice treated with vehicle and BEZ235.
(D) MRIs of representative PB-MYC and Ptenlox/lox mice at initiation and completion of study evaluating PI3K pathway inhibition with BEZ235.
(E) Waterfall plot depicting proportional change in tumor response for PB-MYC (n = 4) and Ptenlox/lox (n = 4) mice treated with vehicle and BEZ235. See also
Figure S1.
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Dual PI3K/AR Pathway Inhibition in Prostate Cancerobserved with BEZ235, albeit to more modest levels (Figure 2F).
We and others previously demonstrated that HER2/HER3
promotes AR activity and stability by an AKT-independent
mechanism by enhancing both AR stability and transcriptional
activity, similar to the effects observed here with BEZ235
(Mahajan et al., 2007; Mellinghoff et al., 2004; Yeh et al., 1999).
Therefore, we postulated that the increase in HER3 expression
induced by PI3K pathway inhibition might explain the increasein AR transcriptional output,. Consistent with this hypothesis,
cotreatment with the HER family kinase inhibitor PKI166
(EGFR and HER2 inhibitor) abolished the upregulation of AR
activity observed with BEZ235, RAD001, or AKT1/2 inhibitor
(Figure 2G).
To address the potential role of ERK activation in the upregula-
tion of AR activity, we examined the effects of MEK inhibition
using theMEK inhibitor PD0325901. In contrast to the stimulatoryCancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc. 577
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Figure 2. Inhibition of the PI3K Pathway Restores, in Part, Androgen-Responsive Signaling in PTEN-Loss Prostate Cancers
(A) AR protein levels by western blot analysis in wild-type, Ptenlox/lox, and Ptenlox/lox mice treated with BEZ235. Ventral prostates from individual 8-week-old mice
were analyzed.
(B) Western blot analysis of AR, pAKT, pS6, and pERK in the LNCaP cell line treated for 24 hr with DMSO, BEZ235 (500 nM), and RAD001 (100 nM).
(C) Expression analysis (qRT-PCR) of the androgen-regulated genes Pbsn, Nkx3.1, and Psca in wild-type, Ptenlox/lox, and Ptenlox/lox mice treated
withBEZ235,normalized toHprtandwild-type intactmice.Ventral prostates from individual8-week-oldmicewereanalyzed, andmean foldchange±SD is reported.
(D) Luciferasemean fold change ±SDmeasurements in the LNCaP AR-ARE-Luciferase cell line treated for 24 hr with DMSO, BEZ235 (500 nM), RAD001 (100 nM),
and AKT1/2 inhibitor (1 mM) normalized to DMSO.
(E) Western blot analysis of HER2, HER3, AR, and PSA in the LNCaP cell line treated with DMSO and BEZ235 (500 nM) for 24 hr and Ptenlox/lox mice treated with
BEZ235.
(F) Western blot analysis for HER3, AR, pAKT, and pERK in LNCaP cells treated with BEZ235 or siRNA AKT1/2 for 24 hr.
(G) Luciferasemean fold change ±SDmeasurements in the LNCaP AR-ARE-Luciferase cell line treated for 24 hr with DMSO, BEZ235 (500 nM), RAD001 (100 nM),
with or without PKI166 (5 mM), or PD0325901 (1 mM) normalized to DMSO.
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Figure 3. PTEN-Loss Prostate Cancer Is Associated with Reduced Androgen-Responsive Gene Signaling
(A) Mean summed z score ±SD for an androgen-responsive gene signature in human PTEN-loss and PTEN-normal prostate cancer showing that PTEN-loss
tumors have a reduced androgen-responsive gene signature with corresponding heat map. Significance was determined by the Student’s t test.
(B and C) GSEA showing the (B) Hieronymus et al. (2006) and (C) Nelson et al. (2002) androgen-responsive gene signatures revealed that androgen-responsive
gene signaling is reduced in PTEN-loss human prostate cancers.
(D) Mean ERBB2 expression levels ±SD in PTEN-loss and PTEN-normal prostate cancer. Significance was determined by the Student’s t test. (E) GSEA of
a murine androgen-responsive gene set in Pten-loss prostate cancers compared to an intact wild-type mouse. See also Figure S2 and Tables S1 and S2.
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Dual PI3K/AR Pathway Inhibition in Prostate Cancereffects of BEZ235 and RAD001 on AR signaling, PD0325901 did
not augment AR signaling. Furthermore, PD0325901 did not
reverse AR activation induced by BEZ235 or RAD001, despite
the fact thatERK isactivatedbybothdrugs (Figure2G). Thus, inhi-
bitionof thePI3KpathwayupregulatesAR target geneexpression
in a HER kinase-dependent manner independent of MEK.
PTEN Loss Is Associated with Repression
of Androgen-Responsive Genes
Having demonstrated that inhibition of the PI3K pathway results
in increased AR activity in two prostate cancer models, we
explored the relevance of this finding in human prostate cancer
specimens. Because clinical trials of PI3K pathway inhibitors in
prostate cancer are still in early stages, we asked the reciprocal
question of whether PI3K activation caused by PTEN lossimpairs AR activity in primary human prostate tumors. One
hundred and six tumors from a previously reported Memorial
Sloan-Kettering Cancer Center (MSKCC) data set were desig-
nated PTEN loss or PTEN normal based on PTEN copy number
and PTEN mRNA expression level. These PTEN status assign-
ments were validated by gene set enrichment analysis (GSEA)
showing concordance with a transcriptome-based signature of
PTEN loss developed independently from breast cancer speci-
mens (Figure S2A) (Saal et al., 2007). We then analyzed AR
pathway activation by PTEN status using a previously reported
mRNA signature of AR target genes (Hieronymus et al., 2006).
AR activity was significantly repressed in PTEN-loss prostate
tumors (Student’s t test on summed z score, p < 0.001; Fig-
ure 3A). Consistent with this finding, GSEA of gene sets differen-
tially regulated in PTEN-loss and PTEN-normal prostate tumorsCancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc. 579
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Dual PI3K/AR Pathway Inhibition in Prostate Cancerrevealed that the same androgen-regulated gene set was signif-
icantly repressed in the PTEN-loss cancers (FDR = 0.01, Fig-
ure 3B) (Hieronymus et al., 2006). This association was also
observed with two other independently derived AR target gene
sets (FDR = 0.01 [Nelson et al., 2002], Figure 3C; FDR < 0.001
[Creighton, 2008], data not shown).
Our observation that PI3K inhibition leads to increased HER3
levels in Ptenlox/lox mice and in LNCaP cells raises the possibility
that human tumors with PTEN loss might have decreased
HER2/3 activity. We did not observe significant differences
in HER3mRNA levels, but HER2 (ERBB2) expression was signif-
icantly (p = 0.006) reduced in PTEN-loss prostate cancers
(Figure 3D). Furthermore, HER2 expression was significantly
(p < 0.003) correlated with AR target gene signature output
(Figure S2B).
Because other genomic alterations may impact the interpreta-
tion of the human tumor studies, we examined AR activity in
primary prostate tissue harvested from 8-week-old Ptenlox/lox
mice (with or with Pten deletion) before the onset of prostate
cancer. To define amurine AR gene signature, we first compared
transcriptomes of prostates from wild-type mice to those from
littermates isolated 3 days post-castration (Table S1). In parallel,
we compared transcriptome data from prostates isolated from
intact Pten+/+ (wild-type) and Pten/ mice (without castration).
GSEA revealed that genes up- or downregulated in response
to castration in wild-type mice were significantly enriched in
intact Pten/ prostates compared to intact Pten+/+ prostates,
indicating that Pten loss is associated with reduced AR activity
(Figure 3E). Examination of individual genes revealed that
a substantial number of the genes up- or downregulated by
castration in intact mice are already up- or downregulated in
intact Pten/ mice (Figure S2C and Table S2). Together with
the human prostate tumor data and the BEZ235 treatment
studies, these findings establish that the increase in PI3K activa-
tion associated with PTEN loss impairs AR signaling.
Inhibition of AR Promotes PI3K Activity in PTEN-Loss
Prostate Cancer
Previous studies in mouse models and cell lines have implicated
PTEN loss as a potential cause of castration resistance (Gao
et al., 2006; Zhang et al., 2009). Our finding that PI3K activation
is associated with reduced AR output suggests a potential
explanation, e.g., these tumors are less dependent on AR.
However, it is possible that AR function, albeit low, remains
intact due to low-circulating androgens that remain after castra-
tion. To investigate the potential role of persistent AR signaling in
this context, we evaluated the effect of combined androgen
blockade (surgical castration plus the next generation AR inhib-
itor MDV3100 that impairs AR nuclear translocation and DNA
binding) (Tran et al., 2009) in the Pten/ model. After 7 days of
treatment, mRNA levels of the androgen-regulated genes
Pbsn, Nkx3.1, and Psca were decreased 25- to 50-fold
(Figure S3A), and AR protein levels were primarily cytoplasmic
(Figure 4B), confirming substantial inhibition of AR pathway
output in tumors isolated from treated mice. Despite this magni-
tude of pathway inhibition, tumors showed only modest regres-
sion (mean reduction in tumor volume of 19.2%) without obvious
histologic changes (Figures 4A and 4B; Figure S3B). In addition
there was minimal effect on proliferation as measured by Ki67580 Cancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc.staining (proliferative indices of 0.34 and 0.28 pretreatment
and posttreatment, respectively) (Figure 4B; Figure S3D). In
contrast the same treatment regimen in PB-MYC mice resulted
in profound reductions in tumor volume (mean of 81.42%),
near-complete pathologic responses, and virtually absent Ki67
staining (reduction in proliferative index from 0.554 to 0.012;
p < 0.001) (Figure 4A; Figures S3B–S3D). We conclude that
even combined AR blockade remains ineffective in Pten/
mice.
Although it is formally possible that the 50-fold impairment
in AR output was simply not enough to impair survival of
PTEN-deficient prostate cells, another explanation could be
persistent survival signaling through AKT. Remarkably, AKT
phosphorylation at Ser473 was increased in prostates of
Ptenlox/lox mice following castration. This increase was likely
PI3K pathway dependent because it was inhibited by concurrent
treatment with BEZ235 (Figure 4C). Similar results, including
increased phosphorylation of downstream AKT targets such as
GSK-alpha and PRAS40, were observed in PTEN-negative
LNCaP cells treated with MDV3100 (Figure 4D). We also
observed increased levels of pAKT in the AR-positive cell line
LAPC4 following treatment with MDV3100 (Figure S3E). The
effects of MDV3100 on AKT activation are likely specific to AR
inhibition because siRNA knockdown of AR gave similar results
(Figure 4D), and no change in pAKT levels was observed in
AR-negative PC3 cells (Figure S3F).
The immunophilin FKBP5 is a chaperone for the AKT phospha-
tase PHLPP, and its expression in prostate cancer is androgen
dependent (Gao et al., 2005; Pei et al., 2009). We hypothesized
that AR inhibition would result in reduced FKBP5 expression
and, consequently, lower PHLPP protein levels, and this could
cause increased phosphorylation of AKT. Indeed, FKBP5 and
PHLPP protein levels were both reduced in LNCaP cells treated
with MDV3100 or siRNA AR, and this was accompanied by an
increase in phosphoAKT (Figure 4D). siRNA knockdown of
PHLPP in the LNCaP cell line resulted in increased levels of
pAKT as expected, and importantly, knockdown of FKPB5
resulted in decreased levels of PHLPP and upregulation of
pAKT, phenocopying the effects of MDV3100 (Figure 4E;
Figure S3G). Furthermore, constitutive expression of FKBP5
(CMV-FKBP5) resulted in stable levels of PHLPP and blocked
theupregulation of pAKT in thepresenceofMDV3100 (Figure 4E).
Protein levels of PHLPP were also lower in Ptenlox/lox mice
following castration (Figure 4F). These data suggest that AR
negatively regulates AKT activity through stabilization of PHLPP.
Consequently, AR inhibition destabilizes PHLPP and results in
unchecked AKT activation, especially in the setting of PTEN loss.
Combined PI3K and AR Pathway Inhibition Gives
Profound Tumor Regressions
Taken together, the effects of PI3K inhibitors on the AR pathway
and AR inhibitors on the PI3K pathway in PTEN-deficient pros-
tate cells demonstrate that perturbations in the activity of one
pathway impact signaling through the other pathway. Therefore,
we evaluated the effect of combined PI3K and AR pathway inhi-
bition in PTEN-deficient LNCaP cells and in the conditional
Pten/ prostate cancer model. BEZ235 and MDV3100 each
displayedmodest single-agent antiproliferative activity in LNCaP
cells (primarily cytostatic), but neither treatment promoted
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Figure 4. Preclinical Trial of Combined Androgen Blockade in GEM Models of Prostate Cancer
(A) Waterfall plot depicting proportional change in tumor response for PB-MYC (n = 5) and Ptenlox/lox (n = 5) mice treated with castration and MDV3100
(30 mg/kg/day).
(B) Histologic and immunohistochemical staining for AR and ki67 and Ptenlox/lox mice treated with vehicle control or castration and MDV3100 (microscopy
at 2003).
(C) Western blot analysis of prostates from wild-type and Ptenlox/lox mice treated with surgical castration and/or BEZ235 for 7 days. Ventral prostates from
individual 8-week-old mice were analyzed.
(D) Western blot analysis for PHLPP, FKBP5, and pAKT in LNCaP treated with MDV3100 (10 mM) or siRNA AR for 24 hr.
(E) Western blot analysis for PHLPP, FKBP5, and pAKT in LNCaP transfected with siRNA FKBP5. Western blot analysis for PHLPP, FKBP5, and pAKT in LNCaP
transfected with vector control, treated with MDV3100 (10 mM), or transfected with CMV-FKBP5 and treated with MDV3100.
(F) Phlpp immunohistochemistry of intact and castrate Ptenlox/lox mice. See also Figure S3.
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Dual PI3K/AR Pathway Inhibition in Prostate Cancerapoptotic cell death (Figures 5A and 5B). However, the combina-
tion of BEZ235 with MDV3100 led to a profound decrease in cell
number and an increase in cleaved PARP, a marker of apoptosis
(Figures 5A and 5B). To determine if similar effects might be
observed by inhibiting mTORC1 or MEK, we compared the
effects of RAD001 or PD0325901 to BEZ235, alone and in
various combinations, including with MDV3100 (Figures S4A
and S4B). The greatest antiproliferative effect was observed
with combined treatment with BEZ235 andMDV3100, indicatingthat PI3K and/or mTORC1/2 and AR, but not mTORC1 or MEK,
appear to be the most critical targets in this model. Based on our
discovery that inhibition of the PI3K pathway promotes AR
activity in a HER2/3-dependent manner, we reasoned that that
a HER2/3 inhibitor might be similarly efficacious (replacing
MDV3100) in combination with BEZ235. Indeed, combined
treatment with BEZ235 and PKI166 was as effective as
BEZ235 plus MDV3100 (Figures 5C and 5D). Furthermore,
inhibition of HER2/3 abolished the upregulation of AR proteinCancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc. 581
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Figure 5. Therapeutic Efficacy of Combined Androgen Blockade and PI3K Pathway Inhibition in Preclinical Models of Prostate Cancer
(A) LNCaP cell proliferation assay reported as mean cell count ±SD following treatment with DMSO, MDV3100 (10 mM), BEZ235 (500 nM), and combinations.
(B) Western blot analysis of LNCaP cells treated with DMSO, MDV3100, BEZ235, and BEZ235/MDV3100 for cleaved-PARP, pAKT, AKT, and pS6.
(C) LNCaP cell proliferation assay reported as mean cell count ±SD following treatment with DMSO, MDV3100 (10 mM), PKI166 (5 mM), and combinations.
(D) Western blot analysis of LNCaP cells treated with DMSO, PKI166, BEZ235, and BEZ235/PKI166 for cleaved-PARP, pAKT, pERK, pS6, and PSA.
(E) MRIs of representative Ptenlox/lox mice at initiation and completion of study evaluating combined AR and PI3K pathway inhibition with castration, MDV3100
(30 mg/kg/day), and BEZ235 (45 mg/kg/day).
(F) Waterfall plot depicting proportional change in tumor response for Ptenlox/lox (n = 4) and PB-MYC (n = 4) mice treated with combined AR and PI3K pathway
inhibition.
(G) Model of PI3K pathway and AR crosstalk demonstrating activation of the PI3K pathway in the setting of PTEN loss leads to up-stream feedback inhibition on
receptor tyrosine kinases (HER2/3) leading to repressed AR activity. Inhibition of the PI3K pathway stimulates up-stream HER2/3 resulting in activation of AR,
whereas blockade of AR reduces FKBP5 levels impairing PHLPP function leading to upregulation of pAKT. See also Figure S4.
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Dual PI3K/AR Pathway Inhibition in Prostate Cancerlevels, and transcriptional activity observed with PI3K pathway
inhibition (Figure 5D), as measured by PSA expression.
To test the impact of combined PI3K/AR therapy in tumor
models, Ptenlox/lox mice with established prostate tumors were
treated with BEZ235 plus MDV3100 and castration. Combined
PI3K and AR pathway inhibition led to dramatic reductions in
tumor volume (mean tumor volume reduction of 84.25%), with
near-complete pathologic responses andno evidence of residual
cell proliferation detectable by Ki67 staining (Figures 5E and 5F;582 Cancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc.Figure S4C). Combined PI3K/AR therapy also induced regres-
sions in LNCaP xenografts (24% mean reduction in tumor
volume), whereas average tumor volume in mice treated with
vehicle or single-pathway therapy (BEZ235 or castration)
increased (28%,30%,and31%, respectively) (FigureS4D).Addi-
tion of BEZ235 to castration plus MDV3100 in PB-MYC mice
showed no measurable benefit, but the substantial response to
combined androgen blockade alone in this model makes it diffi-
cult todetect anyeffect of combinedPI3K/AR therapy (Figure 5F).
Cancer Cell
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AR pathway inhibition has long been the treatment of choice for
men with metastatic prostate cancer. Although much attention
has been devoted to mechanisms of acquired resistance, there
has been little investigation of the considerable variability in
primary response among patients. Here, we show, by mRNA
transcriptome analyses, that activation of the PI3K pathway is
associated with repressed androgen signaling in mouse and
human prostate cancers and that this may, in part, be respon-
sible for the castrate-resistant phenotype observed with these
prostate tumors. Importantly, we demonstrate that this resis-
tance is reversible because inhibition of the PI3K pathway
restores AR signaling in PTEN-deficient prostate cells. At least
one mechanism appears to be through relief of negative
feedback to HER kinases. Similarly, blockade of AR relieves
feedback inhibition of AKT by the phosphatase PHLPP. This
reciprocal feedback regulation of the PI3K and AR pathways
provides a compelling explanation for the poor efficacy of
single-pathway therapy in PTEN null cancers and the substan-
tially better effects of combined PI3K/AR pathway inhibition
(Figure 5G).
Prior work has implicated PTEN loss as a potential cause of
castration resistance in mice and in humans (Gao et al., 2006;
Zhang et al., 2009). Zhang et al. (2009) reported that Pten
prostate conditional null mice treated with surgical castration
have a delay in tumor growth and minimal tumor regression.
Although, to our knowledge, no human studies have formally
addressed this question, there is evidence from presurgical
treatment studies that tumors with PTEN loss are relatively
refractory to bicalutamide (Ham et al., 2009; Schulman et al.,
2000). Despite the evidence that PTEN loss can promote castra-
tion resistance, there is little insight into the mechanism.
Some reports have suggested that PTEN loss activates AR,
through PI3K-mediated stabilization of AR protein levels or
AKT-mediated phosphorylation and transcriptional activation
of AR. Conversely, other studies have demonstrated that PI3K
activation promotes degradation of AR and inhibits AR transcrip-
tional activity (Lin et al., 2003, 2004; Wang et al., 2008). Our
transcriptome studies make a strong case for the latter model.
In addition our finding that reduced expression of the AR target
gene FKBP5 results in an increase in AKT activation (via PHLPP
degradation) in PTEN null cancers further explains the survival
advantage of these tumor cells in the setting of castration.
This work has immediate implications for the design of clinical
trials evaluating PI3K pathway inhibitors in prostate cancer. Our
preclinical data predict that single-agent PI3K pathway inhibitor
therapy will most likely result in disease stabilization rather than
tumor regression, particularly in PTEN null tumors that represent
40%of primary cancers and70%ofmetastases (Taylor et al.,
2010). Additionally, given that the primary serum marker used to
monitor disease progression (prostate-specific antigen or PSA)
is androgen regulated, patients treated with PI3K pathway inhib-
itors may experience a rise in PSA level if their tumors are PTEN
deficient. Our data argue that combined therapy with an AR
pathway inhibitor is required for maximal efficacy in PTEN null
cancers. In patients with hormone-naive disease, this could be
achieved using currently available antiandrogen therapy, but
patients with castration-resistant prostate cancer are likely torequire next-generation AR pathway inhibitors such as abirater-
one or MDV3100.
Because BEZ235 inhibits both PI3K and mTORC1/2, our data
do not delineate which target is most critical for the observed
effects of combination therapy. Others reported beneficial
effects of combined AR and mTORC1 (rapalog) inhibition in
a similar Ptenlox/lox model, but the magnitude of tumor response
was less substantial because mice had significant amounts of
residual tumor tissue at the time of sacrifice (Zhang et al.,
2009). In addition these investigators monitored tumor volume
by ultrasound, which makes it difficult to distinguish between
shrinkage caused by true tumor regression versus a reduction
in the cystic dilation that accompanies Pten/ prostate tumors.
Kinkade et al. (2008) also reported benefit from combining rapa-
mycin with a MEK inhibitor in Nkx3.1/;Pten+/ mice, but this
experiment differs in that Pten+/ mice have a less aggressive
cancer phenotype than the Ptenlox/lox model. Side-by-side
experiments using identical endpoints in the same model are
required to properly compare these regimens. In the meantime
our in vitro studies establish that dual PI3K/mTORC1/2 inhibition
(BEZ235) is superior to mTORC1 inhibition (RAD001) when
combined with AR blockade and that MEK inhibition
(PD0325901) is relatively ineffective. Because BEZ235 inhibits
mTORC1/2 more potently than PI3K, it is possible that the supe-
riority of BEZ235 over RAD001 is solely through TORC1/2
blockade (Serra et al., 2008). This question can be addressed
using selective TORC1/2 inhibitors (Chresta et al., 2010; Thoreen
et al., 2009).
Our finding that HER2/3 activation (and subsequent AR activa-
tion) is associated with PI3K pathway inhibition also has impor-
tant clinical implications because a HER2 kinase inhibitor such
as lapatinib could, in theory, replace the requirement for an
antiandrogen in combination with a PI3K pathway inhibitor.
Our studies with the preclinical HER2 inhibitor PKI-166 establish
this principle in vitro. Single-agent trials with HER2 inhibitors
(trastuzumab, pertuzumab, lapatinib) in men with castration-
resistant prostate cancer have been largely negative (Solit and
Rosen, 2007), but our data suggest that combination of these
inhibitors with PI3K pathway inhibitors is required to elicit
activity.
In summary our results demonstrate that inhibition of the PI3K
pathway in PTEN-negative prostate cancer results in feedback
signaling to the receptor tyrosine kinase HER2/HER3 leading
to activation of AR. Conversely, blockade of AR results in activa-
tion of AKT through reduced levels of FKBP5 impairing the
stability of PHLPP. This bidirectional crosstalk between two
critical survival pathways in prostate cancer provides the molec-
ular rationale for simultaneously targeting both pathways. The
success of clinical trials evaluating PI3K pathway inhibitors in
prostate cancer could be optimized by enrolling patients with
documented activation of the PI3K pathway and treating in
combination with appropriate AR pathway inhibition.EXPERIMENTAL PROCEDURES
Mouse Models of Prostate Cancer
Animal studies were carried out under protocol 06-07-012 approved by the
MSKCC Institutional Animal Care and Use Committee. Institutional guidelines
for the proper, humane use of animals in research were followed. The GEMCancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc. 583
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Dual PI3K/AR Pathway Inhibition in Prostate Cancermodels of human prostate cancer (PB-MYC and Ptenlox/lox PB-Cre) have been
described previously (Ellwood-Yen et al., 2003; Trotman et al., 2003). Geno-
typing was conducted through our core facility using previously published
primer sets and protocols. PB-MYC (ages 12 and 18 months) and Ptenlox/
lox (age 6 months) were imaged by our MRI small animal imaging core prior
to and at the completion of treatment (see Supplemental Experimental Proce-
dures) (Chen et al., 2005). Surgical castration was performed under anesthesia
with isoflurane. Mice were monitored postoperatively for recovery from anes-
thesia and checked daily for 2 days postoperatively. Surgical skin clips were
removed on postoperative day 5. Mice undergoing treatment were adminis-
tered control vehicle or therapeutic doses of the appropriate agents by oral
gavage on aMonday through Friday schedule for a total of 35 days. Anymouse
suffering distress or greater than 15%weight loss during treatment was eutha-
nized by CO2 asphyxiation. MRI tumor volumes were reported for each mouse
at time point zero (T0) at initiation of study and time point 35 days (T35) at
completion of study. Changes in tumor volumes between T0 and T35 were
calculated for individual mice and reported in waterfall plots. At the completion
of study, mice were euthanized by CO2 asphyxiation, and tissue was procured
for histology, mRNA analysis, protein analysis, and tissue banking.
For xenograft experiments, 13 106 LNCaP cells were injected into the bilat-
eral flanks of SCID mice. When mice tumors were approximately 500 mm3,
mice were randomized to the treatment groups. Tumor volume was measured
biweekly for a total of 2 weeks, and the animals were sacrificed according to
our protocol. All animal experiments conform to the relevant regulatory stan-
dards and were approved by our IACUC committee under our approved
animal protocol.
Targeted Pathway Inhibitors
The AR inhibitor MDV3100 was synthesized by the MSKCC chemistry
core and used in vitro at a concentration of 10 mM and in vivo with a dose
of 30 mg/kg/day administered once daily by oral gavage on a Monday through
Friday schedule. The PI3K pathway inhibitors NVP-BEZ235 (PI3K and
mTORC1/2 inhibitor) and RAD001 (mTORC1 inhibitor) were provided by
Novartis under a Materials Transfer Agreement. The concentration of
BEZ235 and RAD001 used for in vitro experiments was 500 and 100 nM,
respectively. For in vivo experiments the dose of BEZ235 used was
45 mg/kg/day administered once daily by oral gavage on a Monday
through Friday schedule. The HER2 kinase inhibitor PKI166 was provided
by Novartis and used for in vitro experiments at a concentration of 5 mM.
PD0325901 (MEK inhibitor) was synthesized by the MSKCC chemistry
core and used for in vitro studies at a concentration of 1 mM. AKT1/2 inhibitor
(AKT VIII) was purchased fromCalbiochem and used in vitro at a concentration
of 1 mM.
Mouse mRNA Expression Analysis
Prostate tissues frozen for total RNA isolation were homogenized in TRIzol
Reagent (Invitrogen; #15596-026), followed by phase separation, washing,
precipitation, and resuspension of RNA in RNase-free water according to
manufacturer’s protocols. The RNA was further purified using the RNeasy kit
(QIAGEN) according to manufacturer’s protocols, followed by quantification
and normalization using A260/A280. cDNA synthesis from 1 mg RNA was carried
out using the TaqMan Reverse Transcription Reagents (Applied Biosystems)
with random hexamers according to the manufacturer’s protocol. Triplicate
samples for quantitative PCR were run in the realplex Mastercycler (Eppen-
dorf) using the Power SYBR Green PCR Mastermix (Applied Biosystems).
Each reaction contained 1 ml of cDNA in a total volume of 20 ml. DCt for each
gene was determined after normalization to Hprt, and DDCt was calculated
relative to the designated reference sample. Gene expression values were
then expressed as a fold change, calculated by 2DDCt. See Supplemental
Experimental Procedures for primer sequences.
Mouse Microarray Expression Profiling
Microarray gene expression profiling was performed on RNA prepared from
the prostates of wild-type and Ptenlox/lox Pb-Cre intact and castrate mice.
Eight-week-old wild-type (n = 7) and Pten prostate conditional null (n = 7)
mice in the C57B6 background were used. Three mice of each genotype
were castrated. Three days after castration, mice were euthanized, and RNA
was isolated from prostates then profiled on the Illumina MouseRef-8 v2584 Cancer Cell 19, 575–586, May 17, 2011 ª2011 Elsevier Inc.bead arrays. Raw data were imported into Partek Genomics Suite v6.5 where
data were Log2 transformed and quartile normalized. See Supplemental
Experimental Procedures for detailed methods for generation of murine
androgen-responsive gene signature and GSEA.
In Vitro Experiments
In vitro experiments were conducted using the LNCaP and PC3 cell lines
obtained from American Type Culture Collection. LAPC4 and LNCaP
AR-ARE-Luciferase, which expresses exogenous AR and Luciferase expres-
sion under control of an androgen-regulated promoter, have been previously
described (Tran et al., 2009). Proliferation assays were conducted by plating
1 3 105 cells per well of a 12-well cell culture plate and treating with vehicle
(DMSO) control or AR/PI3K inhibitors at the aforementioned concentrations.
Viable cells were counted using a hemocytometer using trypan blue exclusion
on days 1, 3, and 5. Cell lysates for western blot analysis were prepared using
standard RIPA buffer. Luciferase assays were conducted using the Promega
ONE-Glo Luciferase Assay System and measured using a luminometer plate
reader. All in vitro experiments were conducted in triplicate, and standard
deviations were reported. Significance was determined by the Student’s t
test. The FKBP5, PHLPP, AKT1, AKT2, and AR siRNA SMARTpool was
obtained from Dharmacon. Control siRNA luciferase was used for all experi-
ments. The CMV-FKPB5 plasmid was purchased from OriGene.
Immunohistochemical and Western Blotting Antibodies
The antibodies used for western blot analysis and immunohistochemistry were
pAKT Ser473 (Cell Signaling Technology; 1:1000 dilution), pAKT Thr308 (Cell
Signaling Technology; 1:500 dilution), AKT (Cell Signaling Technology;
1:1000 dilution), pS6 Ser240/244 (Cell Signaling Technology; 1:1000 dilution),
pERK Thr202/Tyr204 (Cell Signaling Technology; 1:1000 dilution), ERK (Cell
Signaling Technology; 1:1000 dilution), pPRAS40 Thr246 (Cell Signaling Tech-
nology; 1:1000 dilution), PRAS40 (Cell Signaling Technology; 1:1000 dilution),
pGSK3-a Ser21 (Cell Signaling Technology; 1:1000 dilution), GSK (Cell
Signaling Technology; 1:1000 dilution), PARP (Cell Signaling Technology;
1:1000 dilution), AR N-20 (Santa Cruz Biotechnology; 1:500 dilution), c-MYC
(Epitomics; 1:500 dilution), PHLPP (Bethyl Laboratories; 1:500 dilution),
FKBP5 (Bethyl Laboratories; 1:500 dilution), HER2 (Cell Signaling Technology;
1:1000 dilution), HER3 (Cell Signaling Technology; 1:1000 dilution), and Actin
(Cell Signaling Technology; 1:1000 dilution). All immunohistochemical anal-
yses were conducted by the MSKCC Molecular Cytology Core.
Human CGH and mRNA Profiling
Our human prostate cancer data set has been previously published (Taylor
et al., 2010). All patients provided informed consent, samples were procured,
and the study was conducted under MSKCC Institutional Review Board
approval. Briefly, copy number data were generated on Agilent 244K aCGH
arrays, and mRNA expression data were obtained on Affymetrix Human
Exon 1.0 ST arrays. The complete genomics data set and analytic
methods are reported separately and are available at: http://cbio.mskcc.org/
cancergenomics-dataportal/. PTEN status was determined using primary
hormone-naive tumors that had bothmRNA expression data and copy number
data available (n = 106). Tumorswere classified as showing genomicPTEN loss
(n = 19) if they showed PTEN copy number loss (single copy loss or greater by
aCGH) and/or decreased PTEN mRNA level (z < 2). The remaining tumors
were classified as PTEN normal (n = 87). Expression of the Hieronymus et al.
(2006) androgen-responsive gene set was scored by summing the expression
z scores per tumorwithin our humanprostate cancer cohort. GSEAwas carried
out with the gene level expression from primary hormone-naive tumor set
described above stratified by genomic PTEN status, using Student’s t test on
the collapsed probe sets after normalization. Enrichment of two specific
androgen-responsive gene sets aswell as theMSigDBcuratedgene set collec-
tion (c2 version 5) was tested (1000 permutations by gene set; GenePattern).
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